Losartan Potassium Tablet, Film Coated
Product Images NDC 63187-830

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 63187-830). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 01)

Chemical structure of losartan potassium showing the molecular arrangement of atoms including a biphenyl-tetrazole group and a potassium ion.*

FDA Label Image

Figure 1 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 02)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months for Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis shows study months from 0 to 66, and the y-axis shows percentage of patients from 0 to 16%. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure 2 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 03)

Line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between Atenolol and Losartan Potassium treatments. The graph shows lower stroke incidence with Losartan Potassium and indicates an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 04)

A comparative forest plot chart showing hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol on primary composite outcomes and stroke events (fatal/non-fatal), segmented by overall results and subgroups based on age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD). Symbols indicate sample size proportions and risk favors either Losartan Potassium or Atenolol.*

FDA Label Image

Losartan (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 05)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and Placebo groups. The graph shows cumulative event rates increasing over time with Losartan Potassium represented by a solid line and Placebo by a dotted line. A risk reduction of 16.1% with a p-value of 0.022 is noted on the graph.*

FDA Label Image

63187-830-90 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07)

Losartan Potassium 50 mg film-coated tablets label from Proficient Rx LP. The 90-count tablet bottle label includes NDC 63187-830-90, product ID RL083090, and specifies each tablet contains 50 mg Losartan Potassium USP. Tablets are described as white to off-white, round, film-coated, marked with S and 112 with a score line. Manufacturer is Zhejiang Huahai Pharmaceutical Co., Ltd., China. Storage at 20°-25°C is advised.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.